Angiogenic and lymphangiogenic molecules in hematological malignancies.

Abstract:

:In this review, the role of angiogenic and lymphangiogenic growth factors in hematological malignancies is summarized, alongside with possible therapeutic applications. Recent data demonstrate the importance of angiogenesis in hematologic malignancies including leukemia, lymphoma, and multiple myeloma. Expression of angiogenic polypeptides vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) associate with clinical characteristics in human leukemia and lymphoma, and their serum concentrations serve as predictors of poor prognosis. VEGF and VEGF-C also act as survival factors on leukemia. Furthermore, certain hematological malignancies both produce angiogenic or lymphangiogenic growth factors including VEGF and VEGF-C, and also express their receptors, resulting in the generation of autocrine loops that may support cancer cell survival and proliferation. Inhibition of the action of key regulators of endothelial cell growth, alone or in combination with other antiangiogenic drugs and/or established chemo- or immunotherapy regimens, is a potential target for therapeutic intervention in hematological malignancies.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Orpana A,Salven P

doi

10.1080/10428190290005964

keywords:

subject

Has Abstract

pub_date

2002-02-01 00:00:00

pages

219-24

issue

2

eissn

1042-8194

issn

1029-2403

journal_volume

43

pub_type

杂志文章,评审
  • The benzene metabolites hydroquinone and catechol act in synergy to induce dose-dependent hypoploidy and -5q31 in a human cell line.

    abstract::Chronic exposure to high concentrations of benzene is associated with an increased incidence of myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). Studies of patients occupationally exposed to benzene show a pattern of cytogenetic aberrations involving loss of all or part of chromosomes 5 and/or 7 as...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199909145730

    authors: Stillman WS,Varella-Garcia M,Irons RD

    更新日期:1999-10-01 00:00:00

  • Neurological presentation of Hodgkin lymphoma in the Italian Association of Pediatric Hematology and Oncology LH-2004 protocol.

    abstract::Neurological symptoms can represent the first clinical manifestation of central nervous system (CNS) involvement in Hodgkin lymphoma (HL). Because of its rarity, it is often misunderstood for other pathological processes. We report two cases of pediatric CNS HL, presenting with neurological symptoms at diagnosis. We h...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2011.562573

    authors: Burnelli R,Fabbri E,Guerrini G,Sperlì D,D'ambrosio A

    更新日期:2011-06-01 00:00:00

  • Sub-clinical dissemination of follicular lymphoma in normal sized lymph nodes may not be detected by radiologic staging: a case of disseminated follicular lymphoma detected in nodal clearance as part of therapy for cutaneous melanoma.

    abstract::Patients with localized follicular lymphoma are potentially curable; however, the failure rate for local treatment suggests that a proportion of apparently localized disease is being under-staged. We report a case of incidentally diagnosed follicular lymphoma found in association with a stage II malignant melanoma, wi...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190500305596

    authors: Dickinson M,Wotherspoon A,Cunningham D

    更新日期:2006-03-01 00:00:00

  • Dose reductions in ibrutinib therapy are not associated with inferior outcomes in patients with chronic lymphocytic leukemia (CLL).

    abstract::Ibrutinib is a first-in-class small molecule inhibitor that has shown remarkable efficacy in the treatment of CLL. Current guidelines recommend lifelong administration at a fixed daily dose of 420 mg. Data from real-world studies indicate up to 17.5% of patients discontinue ibrutinib due to toxicity. Hypothetically, j...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2018.1554862

    authors: Akhtar OS,Attwood K,Lund I,Hare R,Hernandez-Ilizaliturri FJ,Torka P

    更新日期:2019-07-01 00:00:00

  • The BH3-only protein Puma plays an essential role in p53-mediated apoptosis of chronic lymphocytic leukemia cells.

    abstract::The purpose of this study was to explore the characteristics and functions of BH3-only proteins Puma, Noxa and Bim in the prognosis, therapy and drug resistance of chronic lymphocytic leukemia (CLL). Puma, Noxa and Bim mRNAs were evaluated by real-time quantitative reverse transcriptase-polymerase chain reaction, and ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2013.787613

    authors: Zhu HJ,Liu L,Fan L,Zhang LN,Fang C,Zou ZJ,Li JY,Xu W

    更新日期:2013-12-01 00:00:00

  • Increased circulating CD3+ T cells are associated with early relapse following autologous hematopoietic stem cell transplantation in patients with classical Hodgkin lymphoma.

    abstract::Non-malignant host immune cells are the main substrate in classical Hodgkin lymphoma (HL) microenvironment. Reconstitution of lymphocyte populations following the high-dose chemotherapy (HDC) with autologous hematopoietic stem cell transplantation (auto-HSCT) can support tumor growth in HL patients. We investigated re...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2019.1581934

    authors: Batorov EV,Pronkina NV,Tikhonova MA,Kryuchkova IV,Sergeevicheva VV,Sizikova SA,Ushakova GY,Aristova TA,Batorova DS,Shishkova IV,Gilevich AV,Shevela EY,Ostanin AA,Chernykh ER

    更新日期:2019-10-01 00:00:00

  • Identification of potential ibrutinib combinations in hematological malignancies using a combination high-throughput screen.

    abstract::Matrix high-throughput screening (HTS) methods are increasingly employed to rapidly define potential therapeutic drug combinations. We used combination HTS to identify compounds showing synergistic anti-proliferative activity with ibrutinib, an irreversible, small-molecule inhibitor of Bruton's tyrosine kinase. The go...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2017.1349899

    authors: Schaffer M,Chaturvedi S,Davis C,Aquino R,Stepanchick E,Versele M,Liu Y,Yang J,Lu R,Balasubramanian S

    更新日期:2018-04-01 00:00:00

  • Prognostic factors in pediatric Hodgkin lymphoma: experience from a developing country.

    abstract::Pediatric Hodgkin lymphoma is a curable malignancy. The prognostic factors in the low- and middle-income countries are different from the high-income countries. Data of 106 children, including 84 (79.2%) boys and 22 (20.8%) girls were examined. The mean age at presentation was 7.55 ± 2.74 years. Fifty-nine (55.7%) cas...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2019.1665666

    authors: Ghafoor T

    更新日期:2020-02-01 00:00:00

  • Endogenous tumor necrosis factor and doxorubicin sensitivity in leukemic patients.

    abstract::Sensitivity to doxorubicin (DOX) and expression of intracellular endogenous TNF (enTNF) or manganous superoxide dismutase (MnSOD) activity were found to be inversely correlated in leukemic cells from 19 patients (6 acute lymphoblastic leukemia, 13 acute myeloblastic leukemia). In a case with acquired resistance to che...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199809057560

    authors: Watanabe N

    更新日期:1998-08-01 00:00:00

  • Ubiquitin ligases in malignant lymphoma.

    abstract::The highly controlled degradation of proteins via the ubiquitin-proteasome pathway represents a key mechanism for cell regulation and homeostasis. Ubiquitin-dependent proteolysis, carried out in large part by the E3 ubiquitin ligases, is a critical mode of post-translational modification that is important in regulatio...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190410001663635

    authors: Lim MS,Elenitoba-Johnson KS

    更新日期:2004-07-01 00:00:00

  • Novel agents versus chemotherapy as frontline treatment of CLL.

    abstract::Chronic lymphocytic leukemia (CLL) is a neoplastic disorder of mature B lymphocytes. While traditionally treated with combinations of chemoimmunotherapy, the therapeutic options for CLL have expanded in recent years with the emergence of novel oral agents, such as the Bruton tyrosine kinase inhibitor ibrutinib, that a...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428194.2017.1280606

    authors: Piggin A,Bayly E,Tam CS

    更新日期:2017-06-01 00:00:00

  • Fas/Apo-1 (CD95)-mediated and CD95-independent apoptosis of malignant plasma cells.

    abstract::CD95 (Fas/Apo-1) mediates apoptosis in cells of various types. Expression of CD95 and its function were investigated in myeloma cells and most plasma cell lines have been found to be CD95-positive. Anti-CD95 antibody induced apoptosis in these cell lines in a manner dependent on intensity of CD95 expression. Bel-2 exp...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199609045712

    authors: Hata H,Matsuzaki H,Takeya M,Takatsuki K

    更新日期:1996-12-01 00:00:00

  • Analysis of chromosome 6q deletion in EBV-associated NK cell leukaemia/lymphoma.

    abstract::Deletions involving chromosome 6q have been reported in a number of human cancers such as ovarian and breast tumours as well as haematopoietic malignancies. It seems that this region might contain tumour-suppressor genes. Putative natural killer cell lymphomas/leukaemias (NKLL) represent a group of recently characteri...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190290006062

    authors: Ohshima K,Haraokaa S,Ishihara S,Ohgami A,Yoshioka S,Suzumiya J,Kikuchi M

    更新日期:2002-02-01 00:00:00

  • Familial Lymphoproliferative Disorders with Chromosomal Fragile Site Analysis.

    abstract::We have identified a family in which three members developed B-cell lymphoproliferative disorders within a nine month period. The 33 year old proband and his mother have hairy cell leukemia, and his 37 year old brother developed a large cell lymphoma. Chromosomal fragile site analysis of peripheral blood lymphocytes o...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199109067623

    authors: Moormeier JA,Neilly ME,Vardiman JW,Le Beau MM,Golomb HM

    更新日期:1991-01-01 00:00:00

  • Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study.

    abstract::Patients with chronic lymphocytic leukemia (CLL) who fail fludarabine (Fluda) therapy have a poor response to subsequent salvage regimens and a poor prognosis. This study was undertaken to determine the efficacy and toxicity of a cis-platinum, (cis-p)fluda and arabinosyl cytosine (ara-C) combination in patients who we...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.3109/10428199909145949

    authors: Giles FJ,O'Brien SM,Santini V,Gandhi V,Plunkett W,Seymour JF,Robertson LE,Kantarjian HM,Keating MJ

    更新日期:1999-12-01 00:00:00

  • Is inactivation of O6-methylguanine DNA methyltransferase still a favorable prognostic factor of patients with diffuse large B-cell lymphoma in the era of R-CHOP chemotherapy?

    abstract::The prognostic significance of O6-methylguanine DNA methyltransferase (MGMT) inactivation was evaluated in patients with diffuse large B-cell lymphoma (DLBCL) who received cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in addition to rituximab. In this retrospective study, we used the methylation-sp...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190903312462

    authors: Lee GW,Kang JH,Kim IS,Kim HG,Ko GH,Lee JH,Kim DC,Song DH,Yang JW,Lee JS

    更新日期:2009-12-01 00:00:00

  • Parenthood in patients with acute promyelocytic leukemia after treatment with arsenic trioxide: a case series.

    abstract::Arsenic trioxide, believed to be a carcinogen and a teratogen, has found its niche in the treatment of acute promyelocytic leukemia (APL). APL is a disease affecting young patients. Post-treatment fertility and outcome of pregnancy are always a concern in a disease with high cure rates. We report a case series of six ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2012.679936

    authors: Gupta S,Bagel B,Gujral S,Subramanian PG,Khattry N,Menon H,Nair R

    更新日期:2012-11-01 00:00:00

  • Analysis of HTLV-I in Hodgkin's Disease.

    abstract::Both Epstein-Barr virus (EBV) and the human T-cell leukemia virus I (HTLV-I) have been implicated in the generation of human lymphoproliferative disorders such as Burkitt's lymphoma, Hodgkin's disease (HD) and acute T-cell leukemia (ATL). In Hodgkin's disease EBV has been recently detected in Hodgkin's and Sternberg-R...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199109068088

    authors: Tesch H,Jücker M,Krönke M,Diehl V

    更新日期:1991-01-01 00:00:00

  • Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells.

    abstract::The tyrosine kinase inhibitors (TKIs), nilotinib, ponatinib, and dasatinib (but not bosutinib or imatinib), are associated with vascular adverse events (VAEs) in chronic myeloid leukemia (CML). Though the mechanism is inadequately understood, an effect on vascular cells has been suggested. We investigated the effect o...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2018.1466294

    authors: Gover-Proaktor A,Granot G,Pasmanik-Chor M,Pasvolsky O,Shapira S,Raz O,Raanani P,Leader A

    更新日期:2019-01-01 00:00:00

  • Is there a difference in childhood T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma?

    abstract::To distinguish the similarities or differences between T-cell acute lymphoblastic leukaemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL), we retrospectively analyzed the clinical, immunophenotypic, cytogenetic, and molecular characteristics in 37 children diagnosed between December 1990 and December 2003. Compara...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190701509772

    authors: Uyttebroeck A,Vanhentenrijk V,Hagemeijer A,Boeckx N,Renard M,Wlodarska I,Vandenberghe P,Depaepe P,De Wolf-Peeters C

    更新日期:2007-09-01 00:00:00

  • Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis.

    abstract::Nilotinib has shown favorable safety in patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic (CML-CP) or accelerated phase (CML-AP) who failed prior imatinib, and superior efficacy over imatinib in newly diagnosed Ph+ patients with CML-CP. Reported here are the efficacy and sa...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究

    doi:10.3109/10428194.2011.627480

    authors: Nicolini FE,Masszi T,Shen Z,Gallagher NJ,Jootar S,Powell BL,Dorlhiac-Llacer PE,Zheng M,Szczudlo T,Turkina A

    更新日期:2012-05-01 00:00:00

  • Tocilizumab, in search for a role in acute GVHD.

    abstract::Acute graft versus host disease (aGVHD) was first described by Barnes et al. in 1962, who reported a 'secondary disease' in mice after irradiation and infusion of allogeneic spleen cells. The disease manifested as fatal diarrhea and skin abnormalities. They postulated that aGVHD resulted from introducing immunological...

    journal_title:Leukemia & lymphoma

    pub_type: 评论,杂志文章

    doi:10.1080/10428194.2019.1613545

    authors: Gergis U,van Besien K

    更新日期:2019-09-01 00:00:00

  • Analysis of circulating tumor DNA by targeted ultra-deep sequencing across various non-Hodgkin lymphoma subtypes.

    abstract::Although targeted deep sequencing of cell-free DNA (cfDNA) was recently used to investigate tumor somatic mutations in particular subtypes of non-Hodgkin lymphomas (NHLs), the immense genetic heterogeneity across subtypes poses a hurdle to design a universal gene panel applicable for diverse subtypes of NHLs. We desig...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2019.1573998

    authors: Shin SH,Kim YJ,Lee D,Cho D,Ko YH,Cho J,Park WY,Park D,Kim SJ,Kim WS

    更新日期:2019-09-01 00:00:00

  • Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis.

    abstract::The recurring translocation t(1;19) (q23;p13) with TCF3-PBX1 rearrangements are uncommon in adult acute lymphoblastic leukemia (ALL), and their prognostic impact remains to be described in the era of modern chemotherapies. We investigated 427 adult patients with newly diagnosed pre-B ALL, 16 (4%) had t(1;19)(q23;p13) ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1824071

    authors: Yilmaz M,Kantarjian HM,Toruner G,Yin CC,Kanagal-Shamanna R,Cortes JE,Issa G,Short NJ,Khoury JD,Garcia-Manero G,Ravandi F,Kadia T,Konopleva M,Wierda WG,Jain N,Estrov Z,Sasaki K,Pierce S,O'Brien SM,Jabbour EJ

    更新日期:2021-01-01 00:00:00

  • Joint occurrence of Merkel cell carcinoma and non-Hodgkin lymphomas in four Nordic countries.

    abstract::The objective of this study was to assess the reciprocal association between non-Hodgkin lymphoma (NHL) and Merkel cell carcinoma (MCC) using the data of four Nordic Cancer Registries. Data for this study were drawn from the Danish, Finnish, Norwegian, and Swedish cancer registries. Standardized incidence ratios (SIRs...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2015.1040010

    authors: Koljonen V,Rantanen M,Sahi H,Mellemkjær L,Hansen BT,Chen T,Hemminki K,Pukkala E

    更新日期:2015-01-01 00:00:00

  • A Novel Cell Line (NCU-L-1) from a Patient with Acute Lymphoblastic Leukemia, FAB, L3, Burkitt's Type.

    abstract::A novel cultured cell line, NCU-L-1, was established from a 71-year-old Japanese woman with acute lymphoblastic leukemia, L3 FAB, Burkitt's type. The NCU-L-1 cells were shown to have a mature B-cell phenotype on the basis of immunologic surface marker analysis; including IgG Lambda surface immunoglobulins, CD19, CD20 ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199009050977

    authors: Nitta M,Iwaki O,Wakita A,Kodama H,Takeuchi G,Takada K,Mitomo Y,Yamamoto M,Amano M,Murate T,Koike K,Osada H,Ueda R,Shamoto M

    更新日期:1990-01-01 00:00:00

  • A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma.

    abstract::The purpose of this phase 2 study was to determine the activity and safety of six cycles of bendamustine and eight rituximab (RB) as first-line treatment of adult patients with advanced stage non-follicular indolent non-Hodgkin lymphomas (INFL). The primary end-point was the complete response rate (CRR) with expected ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究

    doi:10.3109/10428194.2015.1091934

    authors: Luminari S,Goldaniga M,Cesaretti M,Orsucci L,Tucci A,Pulsoni A,Salvi F,Arcaini L,Carella AM,Tedeschi A,Pinto A,Stelitano C,Baldini L

    更新日期:2016-01-01 00:00:00

  • Excellent outcomes for adolescents and adults with acute lymphoblastic leukemia and lymphoma without allogeneic stem cell transplant: the FRALLE-93 pediatric protocol.

    abstract::Adolescents and adults with acute lymphoblastic leukemia/lymphoma (ALL) have better outcomes when treated using pediatric protocols compared with treatment using adult protocols. We reviewed the progress and outcomes of 40 adolescents and adults up to 45 years of age, from three Australian centers, treated on the inte...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.3109/10428194.2014.894191

    authors: Hocking J,Schwarer AP,Gasiorowski R,Patil S,Avery S,Gibson J,Iland H,Ho PJ,Joshua D,Muirhead J,Lai H,Irving I

    更新日期:2014-12-01 00:00:00

  • Relevance of in vitro leukaemia cell survival to short- and long term clinical outcome in AML.

    abstract::In ninety-three cases of newly diagnosed acute myeloid leukaemia (AML) we investigated the importance to short- and long term clinical outcome of the in vitro short term leukaemia cell survival as measured by a 4-day MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide)-assay. In 67 patients treated by i...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.3109/10428199909167393

    authors: Nørgaard JM,Jensen PD,Bendix K,Clausen N,Palshof T

    更新日期:1999-01-01 00:00:00

  • Cost-effectiveness of a transplantation strategy compared to melphalan and prednisone in younger patients with multiple myeloma.

    abstract::High dose chemotherapy with autologous stem cell transplantation (ASCT) improves outcomes in patients 65 years of age or less with multiple myeloma. Survival and costs in a cohort of 16 patients who received melphalan and prednisone as part of a clinical trial were compared with those of 36 patients referred to our ce...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.3109/10428190309178811

    authors: Kouroukis CT,O'Brien BJ,Benger A,Marcellus D,Foley R,Garner J,Ingram C,Haines P,Henderson-O'Connor N,Meyer R

    更新日期:2003-01-01 00:00:00